Dr Reddys Laboratories Stock Z Score
RDY Stock | USD 73.35 1.04 1.44% |
RDY | Z Score |
RDY Z Score Analysis
Dr Reddys' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
More About Z Score | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 41.6B | 48.9B | 56.2B | 59.0B | Total Assets | 296.7B | 322.9B | 371.3B | 206.1B |
Z Score | = | Sum Of | | 5 Factors |
Current Dr Reddys Z Score | 3.8 |
Most of Dr Reddys' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
RDY Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as Z Score. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Dr Reddys Laboratories has a Z Score of 3.8. This is 43.7% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The z score for all United States stocks is 56.42% higher than that of the company.
RDY Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in z score category among related companies.
Dr Reddys Institutional Holders
Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.Shares | Gqg Partners Llc | 2023-12-31 | 437 K | Ameriprise Financial Inc | 2023-09-30 | 434.5 K | Millennium Management Llc | 2023-09-30 | 361.6 K | Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 329.1 K | Lazard Asset Management Llc | 2023-09-30 | 306.1 K | Acadian Asset Management Llc | 2023-09-30 | 270.3 K | Schroder Investment Management Group | 2023-12-31 | 266.7 K | Mondrian Investment Partners Ltd | 2023-09-30 | 216.1 K | Assenagon Asset Management Sa | 2023-12-31 | 196.1 K | Blackrock Inc | 2023-12-31 | 3 M | Royal Bank Of Canada | 2023-09-30 | 2.1 M |
RDY Fundamentals
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.19 % | ||||
Operating Margin | 0.25 % | ||||
Current Valuation | 11.45 B | ||||
Shares Outstanding | 166.52 M | ||||
Shares Owned By Institutions | 14.97 % | ||||
Number Of Shares Shorted | 709.29 K | ||||
Price To Earning | 31.58 X | ||||
Price To Book | 3.75 X | ||||
Price To Sales | 0.05 X | ||||
Revenue | 245.88 B | ||||
Gross Profit | 113.84 B | ||||
EBITDA | 108.78 B | ||||
Net Income | 60.48 B | ||||
Cash And Equivalents | 2.93 B | ||||
Cash Per Share | 208.58 X | ||||
Total Debt | 13.47 B | ||||
Debt To Equity | 0.12 % | ||||
Current Ratio | 1.98 X | ||||
Book Value Per Share | 1,609 X | ||||
Cash Flow From Operations | 58.87 B | ||||
Short Ratio | 2.90 X | ||||
Earnings Per Share | 3.75 X | ||||
Price To Earnings To Growth | 4.77 X | ||||
Target Price | 78.13 | ||||
Number Of Employees | 25.86 K | ||||
Beta | 0.35 | ||||
Market Capitalization | 12.29 B | ||||
Total Asset | 322.85 B | ||||
Retained Earnings | 215.59 B | ||||
Working Capital | 118.53 B | ||||
Current Asset | 1.81 B | ||||
Current Liabilities | 976 M | ||||
Z Score | 3.8 | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 0.72 % | ||||
Net Asset | 322.85 B | ||||
Last Dividend Paid | 40.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Piotroski F Score and Dr Reddys Valuation analysis. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.75 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.